{"a":[{"_":"Why early de-risking is redefining the path to IND","$":{"href":"/sponsored/why-early-de-risking-redefining-path-ind","hreflang":"en"}}]}

Summary

Lonza publishes sponsored content explaining early de-risking strategies for biotech teams working to reach IND (Investigational New Drug) status. The article discusses strategic approaches to reducing risk in the early development pathway.